Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Intersect ENT, Inc. (XENT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
26.940.00 (0.00%)
At close: 4:00PM EDT
26.94 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement

Intersect ENT, Inc.

1555 Adams Drive
Menlo Park, CA 94025
United States
650 641 2100
http://www.intersectent.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees406

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas A. WestPres, CEO & Director908.97kN/A1964
Mr. Richard A. MeierExec. VP & CFO621.76kN/A1960
Mr. Patrick A. BroderickExec. VP, Gen. Counsel & Corp. Sec.138.46kN/A1959
Ms. Reyna M. FernandezChief Human Resource Officer115.96kN/AN/A
Mr. Drake R. ParkerAdvisor of Strategic InitiativesN/AN/A1964
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

Corporate Governance

Intersect ENT, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 7; Board: 1; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement